Institut Sainte Catherine — Clinical Trial Site

73 Registered trials

30 Currently recruiting

Organisation

Institut Sainte Catherine

Location

Avignon, France

Identifier

ORG-100042952

Address

250 Chemin De Baigne Pieds, 84000, France

Departments

033007:Medical Oncology
Breast Oncology
Département de dermatologie
Département de radiothérapie
Digestive Oncology
Internal Medicine
Medical Oncology
Medical Oncology Department
NA
Oncologie
Oncologie Médicale
Oncologie- Radiothérapie
Oncology
Oncology - radiotherapy
Oncology Radiotherapy
Oncology-Radiotherapy
Radiology/Oncology
Radiotherapy
Recherche clinique, cancerologie
Service d'oncologie
Service d'oncologie médicale
Service d'Oncologie-Radiothérapie
Service d’Oncologie Médicale
Service de Pneumologie
Service De Radiotherapie
Service Oncologie
Unite Onco-Digestif

Clinical trials at this site (73)

Search interface

Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised

2022-501562-22-00 Triple-negative breast cancer (TNBC) patients at high r 4
ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending

2024-517285-41-00 Newly diagnosed prostate cancer with pelvic lymph nodes 5
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w… Pending

2025-521437-88-00 head and neck squamous cell carcinoma 4
Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w… Pending

2025-521909-40-00 Patients with metastatic or locally advanced HER2-low t 4
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
Improving the empowerment in patients with severe breast fibrosis radio-induced treated by Pravastatin : benefit of e-PROs (electronic « Pat… Recruiting

2024-515342-16-00 Patients with severe and radio-induced breast fibrosis 4 2024-09-05
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting

2022-501562-22-01 Triple-negative breast cancer (TNBC) patients at high r 4 2026-01-05
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc… Recruiting

2023-510558-18-00 locally advanced head and neck squamous cell carcinoma 4 2025-10-13
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Esophageal Squamous Cell Carcinoma (ESCC) 5 2025-07-31
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting

2024-518991-30-00 kidney cancer 6 2025-07-17
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a ran… Recruiting

2023-503326-39-00 Synchronous oligometastatic non-small cell lung cancer 5 2025-03-06
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i… Recruiting

2024-514899-41-00 Breast cancer 4 2024-10-31
Ezabenlimab (BI 754091) and DCFm (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy for the treatment of stage III anal… Recruiting

2024-514083-31-00 squamous cell anal carcinoma 4 2024-07-26